ArticleFrontiers in endocrinology2021
Chondroitin Sulfate Alleviates Diabetic Osteoporosis and Repairs Bone Microstructure
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 45 citations in OpenAlex.
- Preliminary Comparative Analysis of Circulatory Glycosaminoglycan Concentrations and Disaccharide Profiles in Diabetic and Healthy Subjects.The Eurasian journal of medicine · 2026Article
- Molecular mechanisms and structure-activity relationships of natural polysaccharides in ameliorating type 2 diabetes mellitus: a comprehensive review.Frontiers in nutrition · 2026Review
- An Osteoconductive Janus Hydrogel with Full Barrier Protection and Adaptable Degradation Properties for Superior Bone Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Intake of eggshell membrane enhances bone mass and suppresses bone marrow adiposity in normal growing rats.Bone reports · 2025Article
- Network Pharmacology and Experimental Validation of the Therapeutic Effect of Baji Capsule on LPS-Induced Osteoporosis.Orthopedic research and reviews · 2025Article
- Molecular mechanisms and targeted therapy of progranulin in metabolic diseases.Frontiers in endocrinology · 2025Review
- Eggshell membrane as promising supplement to maintain bone health: A systematic review.Bone reports · 2024Review
- Mg-ZIF nanozyme regulates the switch between osteogenic and lipogenic differentiation in BMSCs via lipid metabolism.Lipids in health and disease · 2024Article
- Chromium Picolinate Regulates Bone Metabolism and Prevents Bone Loss in Diabetic Rats.Molecules (Basel, Switzerland) · 2024Article
- Intervention effects of low-molecular-weight chondroitin sulfate from the nasal cartilage of yellow cattle on lipopolysaccharide-induced behavioral disorders: regulation of the microbiome-gut-brain axis.Frontiers in nutrition · 2024Article
- Recent progress in bone-repair strategies in diabetic conditions.Materials today. Bio · 2023Review
- Selected Parameters of Bone Turnover in Neuroendocrine Tumors-A Potential Clinical Use?Journal of clinical medicine · 2023Article
- Screening of crosstalk and pyroptosis-related genes linking periodontitis and osteoporosis based on bioinformatics and machine learning.Frontiers in immunology · 2022Article
- Curcumin Prevents Diabetic Osteoporosis through Promoting Osteogenesis and Angiogenesis Coupling via NF-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Hydrogen saline water accelerates fracture healing by suppressing autophagy in ovariectomized rats.Frontiers in endocrinology · 2022Article
- S-Equol enhances osteoblastic bone formation and prevents bone loss through OPG/RANKLFrontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic osteoporosis (DOP) belongs to secondary osteoporosis caused by diabetes; it has the characteristics of high morbidity and high disability. In the present study, we constructed a type 1 diabetic rat model and administered chondroitin sulfate (200 mg/kg) for 10 weeks to observe the preventive effect of chondroitin sulfate on the bone loss of diabetic rats. The results showed that chondroitin sulfate can reduce blood glucose and relieve symptoms of diabetic rats; in addition, it can significantly increase the bone mineral density, improve bone microstructure, and reduce bone marrow adipocyte number in diabetic rats; after 10 weeks of chondroitin sulfate administration, the SOD activity level was upregulated, as well as CAT levels, indicating that chondroitin sulfate can alleviate oxidative stress in diabetic rats. Chondroitin sulfate was also found to reduce the level of serum inflammatory cytokines (TNF-α, IL-1, IL-6, and MCP-1) and alleviate the inflammation in diabetic rats; bone metabolism marker detection results showed that chondroitin sulfate can reduce bone turnover in diabetic rats (decreased RANKL, CTX-1, ALP, and TRACP 5b levels were observed after 10 weeks of chondroitin sulfate administration). At the same time, the bone OPG and RUNX 2 expression levels were higher after chondroitin sulfate treatment, the bone RANKL expression was lowered, and the OPG/RANKL ratio was upregulated. All of the above indicated that chondroitin sulfate could prevent STZ-induced DOP and repair bone microstructure; the main mechanism was through anti-oxidation, anti-inflammatory, and regulating bone metabolism. Chondroitin sulfate could be used to develop anti-DOP functional foods and diet interventions for diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.